Today’s News Headlines
The biggest headline today: the FDA approved a higher 7.2 mg dose of Wegovy, giving some patients and clinicians a new option for chronic weight management. At the same time, FDA guidance this month is pushing back hard on unapproved GLP-1 products as national supply stabilizes—an important reminder that “compounded” is not the same thing as FDA-approved.
(fda.gov)
Today’s Top Stories
FDA approves higher-dose Wegovy (7.2 mg)
The FDA approved Wegovy HD on March 19, 2026 for adults with obesity or overweight with at least one weight-related condition. The agency said the new dose is intended to reduce excess body weight and help maintain weight loss long term.
(fda.gov)
Why it matters: For some patients, dose optimization may improve results without changing medication class. It also signals that obesity treatment is still evolving, not “one-size-fits-all.”
(fda.gov)
Source:
fda.gov
FDA tightens message on compounded GLP-1s as shortages ease
FDA said on April 1, 2026 that tirzepatide and semaglutide do not currently appear on the 503B bulks list or the FDA shortage list, and it reminded compounders that exemption rules still apply. The agency separately warned that fraudulent compounded semaglutide and tirzepatide products have been found with false labeling and other quality concerns.
(fda.gov)
Why it matters: As supply improves, safety and legality around non-approved GLP-1 products become even more important for patients looking for affordable access.
(fda.gov)
Source:
fda.gov
FDA removes suicidal ideation warning request from GLP-1 labels
On January 13, 2026, FDA said it requested removal of the suicidal behavior and ideation warning from GLP-1 RA medications including Wegovy and Zepbound, while still advising patients to continue taking medication as prescribed and discuss concerns with clinicians.
(fda.gov)
Why it matters: This is a meaningful update for patients worried about safety headlines, and it underscores the importance of distinguishing signal from speculation.
(fda.gov)
Source:
fda.gov
Deep Dive: Mindset & Strategy
Today’s theme is about keeping weight loss sustainable when motivation fades. Research and clinical experience keep pointing to the same truth: the plan that works is the one you can repeat on ordinary Tuesdays, not just “perfect” days. The most durable habits are usually boring on paper—protein-forward meals, consistent sleep, walking, strength training, and fewer all-or-nothing rules.
(pubmed.ncbi.nlm.nih.gov)
A useful reframe: your job is not to eat perfectly; it’s to lower the number of decisions that can derail you. That might mean stocking two easy breakfasts, pre-logging dinner, or setting a non-negotiable 10-minute walk after lunch. Small systems beat big bursts of willpower.
(pubmed.ncbi.nlm.nih.gov)
Practical takeaway: If your weight loss has stalled, don’t immediately slash calories harder. First check your “friction points”: sleep, stress, weekend eating, liquid calories, and whether your environment makes the healthy choice harder than it should be.
(pubmed.ncbi.nlm.nih.gov)
Quick Hits
- FDA says certain GLP-1 compounding workarounds are no longer appropriate now that supply is stabilizing.
(fda.gov) - FDA guidance released in March 2026 now addresses weight-loss-related medical devices, hinting that non-drug obesity treatment innovation is also accelerating.
(fda.gov) - Real-world data continue to show tirzepatide can produce clinically meaningful short-term weight loss even at low doses, though this was observational and not proof of superiority.
(pubmed.ncbi.nlm.nih.gov) - A recent semaglutide study found weight loss was accompanied by reductions in fat mass and preserved lean mass/function in patients with obesity.
(pubmed.ncbi.nlm.nih.gov) - A 2025 head-to-head comparison reported greater weight loss with tirzepatide than semaglutide in adults with obesity without diabetes, though side effects occurred in both groups.
(clinician.nejm.org) - FDA continues to warn consumers about illegal GLP-1 products marketed for research use or mislabeled for human use.
(fda.gov)
By The Numbers
17.8% — In FDA-reviewed evidence, tirzepatide 15 mg produced a placebo-adjusted mean weight-loss difference of 17.8% at 72 weeks in adults with obesity/overweight without diabetes.
(accessdata.fda.gov)
What it means: That’s a large effect size in obesity medicine, but it reflects a clinical trial context with structured follow-up and dose titration.
(accessdata.fda.gov)
Why readers should care: It helps explain why GLP-1/GIP medications are reshaping treatment expectations—while also reminding us that long-term adherence and access still matter.
(accessdata.fda.gov)
Ask The Community
What’s the one habit that has helped you most: meal planning, walking, strength training, sleep, tracking, or something else?
Tomorrow’s Preview
Tomorrow we’ll go deeper on the science of appetite, protein, and why some people feel “stuck” even when they’re doing many things right.